nodes	percent_of_prediction	percent_of_DWPC	metapath
Epirubicin—Doxorubicin—muscle cancer	0.212	1	CrCtD
Epirubicin—Anthracyclines—Doxorubicin—muscle cancer	0.122	0.427	CiPCiCtD
Epirubicin—Topoisomerase Inhibitors—Etoposide—muscle cancer	0.0999	0.35	CiPCiCtD
Epirubicin—Topoisomerase Inhibitors—Doxorubicin—muscle cancer	0.0636	0.223	CiPCiCtD
Epirubicin—Daunorubicin—Doxorubicin—muscle cancer	0.045	0.333	CrCrCtD
Epirubicin—Valrubicin—Doxorubicin—muscle cancer	0.045	0.333	CrCrCtD
Epirubicin—Idarubicin—Doxorubicin—muscle cancer	0.045	0.333	CrCrCtD
Epirubicin—hematologic cancer—muscle cancer	0.0375	0.201	CtDrD
Epirubicin—uterine cancer—muscle cancer	0.0308	0.164	CtDrD
Epirubicin—YWHAG—Doxorubicin—muscle cancer	0.0293	0.229	CbGbCtD
Epirubicin—AURKA—Doxorubicin—muscle cancer	0.0293	0.229	CbGbCtD
Epirubicin—DHCR7—Doxorubicin—muscle cancer	0.0293	0.229	CbGbCtD
Epirubicin—urinary bladder cancer—muscle cancer	0.0288	0.154	CtDrD
Epirubicin—bone cancer—muscle cancer	0.0276	0.147	CtDrD
Epirubicin—testicular cancer—muscle cancer	0.0229	0.122	CtDrD
Epirubicin—peripheral nervous system neoplasm—muscle cancer	0.0202	0.108	CtDrD
Epirubicin—sarcoma—muscle cancer	0.0195	0.104	CtDrD
Epirubicin—TOP2A—Etoposide—muscle cancer	0.00873	0.0683	CbGbCtD
Epirubicin—ABCC1—Dactinomycin—muscle cancer	0.00857	0.0671	CbGbCtD
Epirubicin—TOP2A—Doxorubicin—muscle cancer	0.00595	0.0466	CbGbCtD
Epirubicin—ABCC1—Vincristine—muscle cancer	0.00528	0.0413	CbGbCtD
Epirubicin—ABCC1—Etoposide—muscle cancer	0.00484	0.0379	CbGbCtD
Epirubicin—ABCC1—Doxorubicin—muscle cancer	0.0033	0.0258	CbGbCtD
Epirubicin—ABCC1—Methotrexate—muscle cancer	0.0032	0.025	CbGbCtD
Epirubicin—YWHAG—Translocation of GLUT4 to the plasma membrane—ASPSCR1—muscle cancer	0.000401	0.0883	CbGpPWpGaD
Epirubicin—CHD1—cardiac atrium—muscle cancer	0.000372	0.0449	CbGeAlD
Epirubicin—AURKA—renal system—muscle cancer	0.000335	0.0404	CbGeAlD
Epirubicin—CHD1—tendon—muscle cancer	0.000324	0.0391	CbGeAlD
Epirubicin—YWHAG—Regulation of nuclear beta catenin signaling and target gene transcription—MYF5—muscle cancer	0.000323	0.0711	CbGpPWpGaD
Epirubicin—CHD1—bone marrow—muscle cancer	0.000314	0.0379	CbGeAlD
Epirubicin—CHD1—vagina—muscle cancer	0.000301	0.0363	CbGeAlD
Epirubicin—CHD1—head—muscle cancer	0.000278	0.0335	CbGeAlD
Epirubicin—CHD1—testis—muscle cancer	0.000268	0.0324	CbGeAlD
Epirubicin—YWHAG—smooth muscle tissue—muscle cancer	0.000267	0.0322	CbGeAlD
Epirubicin—AURKA—tendon—muscle cancer	0.000261	0.0315	CbGeAlD
Epirubicin—YWHAG—renal system—muscle cancer	0.000257	0.031	CbGeAlD
Epirubicin—AURKA—bone marrow—muscle cancer	0.000253	0.0305	CbGeAlD
Epirubicin—DHCR7—cardiac atrium—muscle cancer	0.000251	0.0303	CbGeAlD
Epirubicin—AURKA—vagina—muscle cancer	0.000242	0.0293	CbGeAlD
Epirubicin—UGT2B7—renal system—muscle cancer	0.000232	0.028	CbGeAlD
Epirubicin—YWHAG—cardiac atrium—muscle cancer	0.00023	0.0278	CbGeAlD
Epirubicin—AURKA—head—muscle cancer	0.000224	0.027	CbGeAlD
Epirubicin—AURKA—testis—muscle cancer	0.000216	0.0261	CbGeAlD
Epirubicin—DHCR7—bone marrow—muscle cancer	0.000212	0.0255	CbGeAlD
Epirubicin—YWHAG—Regulation of nuclear beta catenin signaling and target gene transcription—MYOG—muscle cancer	0.000208	0.0458	CbGpPWpGaD
Epirubicin—DHCR7—vagina—muscle cancer	0.000203	0.0245	CbGeAlD
Epirubicin—YWHAG—tendon—muscle cancer	0.0002	0.0242	CbGeAlD
Epirubicin—PLA2G4A—smooth muscle tissue—muscle cancer	0.000199	0.024	CbGeAlD
Epirubicin—YWHAG—bone marrow—muscle cancer	0.000194	0.0234	CbGeAlD
Epirubicin—PLA2G4A—renal system—muscle cancer	0.000192	0.0231	CbGeAlD
Epirubicin—DHCR7—head—muscle cancer	0.000187	0.0226	CbGeAlD
Epirubicin—YWHAG—vagina—muscle cancer	0.000186	0.0225	CbGeAlD
Epirubicin—DHCR7—testis—muscle cancer	0.000181	0.0218	CbGeAlD
Epirubicin—AURKA—PLK1 signaling events—BUB1B—muscle cancer	0.000179	0.0395	CbGpPWpGaD
Epirubicin—YWHAG—head—muscle cancer	0.000172	0.0207	CbGeAlD
Epirubicin—YWHAG—Class I PI3K signaling events mediated by Akt—FOXO4—muscle cancer	0.000169	0.0373	CbGpPWpGaD
Epirubicin—YWHAG—testis—muscle cancer	0.000166	0.02	CbGeAlD
Epirubicin—YWHAG—Membrane Trafficking—ASPSCR1—muscle cancer	0.000161	0.0356	CbGpPWpGaD
Epirubicin—UGT2B7—testis—muscle cancer	0.00015	0.0181	CbGeAlD
Epirubicin—PLA2G4A—tendon—muscle cancer	0.00015	0.018	CbGeAlD
Epirubicin—TOP2A—Validated transcriptional targets of deltaNp63 isoforms—TP63—muscle cancer	0.000145	0.032	CbGpPWpGaD
Epirubicin—PLA2G4A—bone marrow—muscle cancer	0.000145	0.0175	CbGeAlD
Epirubicin—TOP2A—tendon—muscle cancer	0.000142	0.0171	CbGeAlD
Epirubicin—PLA2G4A—vagina—muscle cancer	0.000139	0.0167	CbGeAlD
Epirubicin—TOP2A—bone marrow—muscle cancer	0.000138	0.0166	CbGeAlD
Epirubicin—TOP2A—vagina—muscle cancer	0.000132	0.0159	CbGeAlD
Epirubicin—CHD1—Daunorubicin—Doxorubicin—muscle cancer	0.000131	0.169	CbGdCrCtD
Epirubicin—CHD1—Idarubicin—Doxorubicin—muscle cancer	0.000131	0.169	CbGdCrCtD
Epirubicin—YWHAG—FoxO family signaling—FOXO4—muscle cancer	0.000129	0.0285	CbGpPWpGaD
Epirubicin—PLA2G4A—Raltitrexed—Methotrexate—muscle cancer	0.000126	0.162	CbGdCrCtD
Epirubicin—YWHAG—Class I PI3K signaling events mediated by Akt—FOXO1—muscle cancer	0.000125	0.0275	CbGpPWpGaD
Epirubicin—PLA2G4A—testis—muscle cancer	0.000124	0.0149	CbGeAlD
Epirubicin—TOP2A—testis—muscle cancer	0.000118	0.0142	CbGeAlD
Epirubicin—YWHAG—Regulation of nuclear beta catenin signaling and target gene transcription—MED12—muscle cancer	0.000117	0.0259	CbGpPWpGaD
Epirubicin—AURKA—APC/C-mediated degradation of cell cycle proteins—BUB1B—muscle cancer	0.000114	0.0251	CbGpPWpGaD
Epirubicin—AURKA—Aurora A signaling—MDM2—muscle cancer	0.000109	0.024	CbGpPWpGaD
Epirubicin—YWHAG—Myometrial Relaxation and Contraction Pathways—CALD1—muscle cancer	0.000104	0.0229	CbGpPWpGaD
Epirubicin—ABCC1—cardiac atrium—muscle cancer	9.82e-05	0.0118	CbGeAlD
Epirubicin—YWHAG—FoxO family signaling—FOXO1—muscle cancer	9.54e-05	0.021	CbGpPWpGaD
Epirubicin—YWHAG—SIDS Susceptibility Pathways—TP73—muscle cancer	9.23e-05	0.0203	CbGpPWpGaD
Epirubicin—AURKA—Teniposide—Etoposide—muscle cancer	8.93e-05	0.115	CbGdCrCtD
Epirubicin—ABCC1—tendon—muscle cancer	8.55e-05	0.0103	CbGeAlD
Epirubicin—ABCC1—vagina—muscle cancer	7.94e-05	0.00958	CbGeAlD
Epirubicin—YWHAG—Cell Cycle—BUB1B—muscle cancer	7.19e-05	0.0158	CbGpPWpGaD
Epirubicin—ABCC1—testis—muscle cancer	7.08e-05	0.00855	CbGeAlD
Epirubicin—AURKA—EGF/EGFR Signaling Pathway—FOXO4—muscle cancer	6.55e-05	0.0144	CbGpPWpGaD
Epirubicin—AURKA—Aurora A signaling—TP53—muscle cancer	6.25e-05	0.0138	CbGpPWpGaD
Epirubicin—PLA2G4A—AGE/RAGE pathway—FOXO4—muscle cancer	6.17e-05	0.0136	CbGpPWpGaD
Epirubicin—ABCC1—S1P1 pathway—PTGS2—muscle cancer	5.7e-05	0.0126	CbGpPWpGaD
Epirubicin—YWHAG—Activation of BH3-only proteins—TP53—muscle cancer	5.63e-05	0.0124	CbGpPWpGaD
Epirubicin—TOP2A—Vindesine—Vincristine—muscle cancer	5.41e-05	0.0697	CbGdCrCtD
Epirubicin—AURKA—Integrated Breast Cancer Pathway—FOXO1—muscle cancer	5.12e-05	0.0113	CbGpPWpGaD
Epirubicin—PLA2G4A—Prostaglandin Synthesis and Regulation—PTGS2—muscle cancer	4.95e-05	0.0109	CbGpPWpGaD
Epirubicin—AURKA—EGF/EGFR Signaling Pathway—FOXO1—muscle cancer	4.84e-05	0.0107	CbGpPWpGaD
Epirubicin—PLA2G4A—AGE/RAGE pathway—FOXO1—muscle cancer	4.56e-05	0.01	CbGpPWpGaD
Epirubicin—ABCC1—S1P1 pathway—VEGFA—muscle cancer	4.49e-05	0.0099	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling mediated by p38-alpha and p38-beta—PTGS2—muscle cancer	4.38e-05	0.00965	CbGpPWpGaD
Epirubicin—DHCR7—Metabolism of lipids and lipoproteins—MED12—muscle cancer	4.38e-05	0.00964	CbGpPWpGaD
Epirubicin—AURKA—Daunorubicin—Doxorubicin—muscle cancer	4.31e-05	0.0555	CbGdCrCtD
Epirubicin—AURKA—Idarubicin—Doxorubicin—muscle cancer	4.31e-05	0.0555	CbGdCrCtD
Epirubicin—TOP2A—Validated transcriptional targets of deltaNp63 isoforms—CDKN2A—muscle cancer	4.27e-05	0.00941	CbGpPWpGaD
Epirubicin—TOP2A—Integrated Pancreatic Cancer Pathway—WT1—muscle cancer	4.16e-05	0.00917	CbGpPWpGaD
Epirubicin—TOP2A—Validated transcriptional targets of deltaNp63 isoforms—MDM2—muscle cancer	4.14e-05	0.00913	CbGpPWpGaD
Epirubicin—YWHAG—Intrinsic Pathway for Apoptosis—TP53—muscle cancer	4.03e-05	0.00888	CbGpPWpGaD
Epirubicin—YWHAG—Regulation of nuclear beta catenin signaling and target gene transcription—CDKN2A—muscle cancer	3.99e-05	0.00879	CbGpPWpGaD
Epirubicin—YWHAG—LKB1 signaling events—TP53—muscle cancer	3.65e-05	0.00804	CbGpPWpGaD
Epirubicin—PLA2G4A—Integrated Pancreatic Cancer Pathway—WT1—muscle cancer	3.61e-05	0.00795	CbGpPWpGaD
Epirubicin—DHCR7—Metabolism—FH—muscle cancer	3.45e-05	0.0076	CbGpPWpGaD
Epirubicin—TOP2A—Vinorelbine—Vincristine—muscle cancer	3.42e-05	0.044	CbGdCrCtD
Epirubicin—TOP2A—Teniposide—Etoposide—muscle cancer	3.41e-05	0.044	CbGdCrCtD
Epirubicin—TOP2A—Podofilox—Etoposide—muscle cancer	3.41e-05	0.044	CbGdCrCtD
Epirubicin—TOP2A—Gastric Cancer Network 2—TP53—muscle cancer	3.31e-05	0.00731	CbGpPWpGaD
Epirubicin—PLA2G4A—Arachidonic acid metabolism—PTGS2—muscle cancer	3.29e-05	0.00725	CbGpPWpGaD
Epirubicin—YWHAG—Cell Cycle—CDKN2A—muscle cancer	3.28e-05	0.00724	CbGpPWpGaD
Epirubicin—YWHAG—Cell Cycle—MDM2—muscle cancer	3.19e-05	0.00702	CbGpPWpGaD
Epirubicin—AURKA—Integrated Breast Cancer Pathway—MDM2—muscle cancer	3.07e-05	0.00677	CbGpPWpGaD
Epirubicin—TOP2A—Integrated Pancreatic Cancer Pathway—BUB1B—muscle cancer	3.04e-05	0.00671	CbGpPWpGaD
Epirubicin—AURKA—Cell Cycle, Mitotic—BUB1B—muscle cancer	2.78e-05	0.00613	CbGpPWpGaD
Epirubicin—PLA2G4A—Integrated Pancreatic Cancer Pathway—BUB1B—muscle cancer	2.64e-05	0.00581	CbGpPWpGaD
Epirubicin—ABCC1—Arachidonic acid metabolism—PTGS2—muscle cancer	2.63e-05	0.0058	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling mediated by p38-alpha and p38-beta—TP53—muscle cancer	2.61e-05	0.00574	CbGpPWpGaD
Epirubicin—TOP2A—Retinoblastoma (RB) in Cancer—MDM2—muscle cancer	2.53e-05	0.00558	CbGpPWpGaD
Epirubicin—AURKA—Cell Cycle—BUB1B—muscle cancer	2.49e-05	0.00548	CbGpPWpGaD
Epirubicin—TOP2A—Vinblastine—Vincristine—muscle cancer	2.35e-05	0.0302	CbGdCrCtD
Epirubicin—AURKA—Integrated Breast Cancer Pathway—VEGFA—muscle cancer	2.33e-05	0.00514	CbGpPWpGaD
Epirubicin—YWHAG—Cell Cycle, Mitotic—BUB1B—muscle cancer	2.11e-05	0.00464	CbGpPWpGaD
Epirubicin—PLA2G4A—Hemostasis—ANGPT2—muscle cancer	2e-05	0.0044	CbGpPWpGaD
Epirubicin—DHCR7—Metabolism—MED12—muscle cancer	1.95e-05	0.0043	CbGpPWpGaD
Epirubicin—YWHAG—Cell Cycle—BUB1B—muscle cancer	1.88e-05	0.00415	CbGpPWpGaD
Epirubicin—PLA2G4A—Platelet activation, signaling and aggregation—IGF2—muscle cancer	1.88e-05	0.00415	CbGpPWpGaD
Epirubicin—TOP2A—Mitotic G1-G1/S phases—CDKN2A—muscle cancer	1.84e-05	0.00405	CbGpPWpGaD
Epirubicin—YWHAG—Cell Cycle—TP53—muscle cancer	1.83e-05	0.00403	CbGpPWpGaD
Epirubicin—DHCR7—Metabolism—ENO2—muscle cancer	1.78e-05	0.00392	CbGpPWpGaD
Epirubicin—AURKA—Integrated Breast Cancer Pathway—TP53—muscle cancer	1.76e-05	0.00388	CbGpPWpGaD
Epirubicin—YWHAG—SIDS Susceptibility Pathways—VEGFA—muscle cancer	1.72e-05	0.0038	CbGpPWpGaD
Epirubicin—ABCC1—Defective AMN causes hereditary megaloblastic anemia 1—PTGS2—muscle cancer	1.69e-05	0.00372	CbGpPWpGaD
Epirubicin—TOP2A—Idarubicin—Doxorubicin—muscle cancer	1.65e-05	0.0212	CbGdCrCtD
Epirubicin—TOP2A—Daunorubicin—Doxorubicin—muscle cancer	1.65e-05	0.0212	CbGdCrCtD
Epirubicin—PLA2G4A—Metabolism of lipids and lipoproteins—MED12—muscle cancer	1.48e-05	0.00326	CbGpPWpGaD
Epirubicin—TOP2A—Cell Cycle, Mitotic—BUB1B—muscle cancer	1.47e-05	0.00325	CbGpPWpGaD
Epirubicin—TOP2A—Retinoblastoma (RB) in Cancer—TP53—muscle cancer	1.45e-05	0.0032	CbGpPWpGaD
Epirubicin—DHCR7—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	1.39e-05	0.00306	CbGpPWpGaD
Epirubicin—TOP2A—Integrated Pancreatic Cancer Pathway—MDM2—muscle cancer	1.35e-05	0.00297	CbGpPWpGaD
Epirubicin—TOP2A—Cell Cycle—BUB1B—muscle cancer	1.32e-05	0.0029	CbGpPWpGaD
Epirubicin—YWHAG—Apoptosis—TP53—muscle cancer	1.31e-05	0.00288	CbGpPWpGaD
Epirubicin—TOP2A—Integrated Pancreatic Cancer Pathway—PTGS2—muscle cancer	1.3e-05	0.00287	CbGpPWpGaD
Epirubicin—AURKA—Cell Cycle, Mitotic—CDKN2A—muscle cancer	1.27e-05	0.0028	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—KIDINS220—muscle cancer	1.21e-05	0.00267	CbGpPWpGaD
Epirubicin—UGT2B7—Metabolism—FH—muscle cancer	1.19e-05	0.00262	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism of lipids and lipoproteins—MED12—muscle cancer	1.18e-05	0.00261	CbGpPWpGaD
Epirubicin—PLA2G4A—Integrated Pancreatic Cancer Pathway—MDM2—muscle cancer	1.17e-05	0.00258	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism—FH—muscle cancer	1.17e-05	0.00257	CbGpPWpGaD
Epirubicin—AURKA—Cell Cycle—CDKN2A—muscle cancer	1.14e-05	0.0025	CbGpPWpGaD
Epirubicin—PLA2G4A—Integrated Pancreatic Cancer Pathway—PTGS2—muscle cancer	1.13e-05	0.00248	CbGpPWpGaD
Epirubicin—AURKA—Cell Cycle—MDM2—muscle cancer	1.1e-05	0.00243	CbGpPWpGaD
Epirubicin—Breast disorder—Doxorubicin—muscle cancer	1.06e-05	0.000271	CcSEcCtD
Epirubicin—Anorexia—Etoposide—muscle cancer	1.06e-05	0.000271	CcSEcCtD
Epirubicin—Aspartate aminotransferase increased—Doxorubicin—muscle cancer	1.05e-05	0.00027	CcSEcCtD
Epirubicin—Toxic epidermal necrolysis—Doxorubicin—muscle cancer	1.05e-05	0.00027	CcSEcCtD
Epirubicin—Diarrhoea—Dactinomycin—muscle cancer	1.05e-05	0.000269	CcSEcCtD
Epirubicin—Pneumonia—Methotrexate—muscle cancer	1.05e-05	0.000268	CcSEcCtD
Epirubicin—Nasopharyngitis—Doxorubicin—muscle cancer	1.05e-05	0.000268	CcSEcCtD
Epirubicin—Drowsiness—Methotrexate—muscle cancer	1.04e-05	0.000267	CcSEcCtD
Epirubicin—Infestation NOS—Methotrexate—muscle cancer	1.04e-05	0.000267	CcSEcCtD
Epirubicin—Infestation—Methotrexate—muscle cancer	1.04e-05	0.000267	CcSEcCtD
Epirubicin—Hypotension—Etoposide—muscle cancer	1.04e-05	0.000266	CcSEcCtD
Epirubicin—Gastritis—Doxorubicin—muscle cancer	1.04e-05	0.000265	CcSEcCtD
Epirubicin—Stevens-Johnson syndrome—Methotrexate—muscle cancer	1.03e-05	0.000265	CcSEcCtD
Epirubicin—Muscular weakness—Doxorubicin—muscle cancer	1.03e-05	0.000265	CcSEcCtD
Epirubicin—Alanine aminotransferase increased—Doxorubicin—muscle cancer	1.03e-05	0.000265	CcSEcCtD
Epirubicin—Renal failure—Methotrexate—muscle cancer	1.02e-05	0.000262	CcSEcCtD
Epirubicin—TOP2A—Integrated Pancreatic Cancer Pathway—VEGFA—muscle cancer	1.02e-05	0.00226	CbGpPWpGaD
Epirubicin—Abdominal distension—Doxorubicin—muscle cancer	1.02e-05	0.000261	CcSEcCtD
Epirubicin—Stomatitis—Methotrexate—muscle cancer	1.02e-05	0.00026	CcSEcCtD
Epirubicin—Conjunctivitis—Methotrexate—muscle cancer	1.01e-05	0.000259	CcSEcCtD
Epirubicin—Dysphagia—Doxorubicin—muscle cancer	1.01e-05	0.000259	CcSEcCtD
Epirubicin—Influenza—Doxorubicin—muscle cancer	1.01e-05	0.000259	CcSEcCtD
Epirubicin—Asthma—Doxorubicin—muscle cancer	1.01e-05	0.000259	CcSEcCtD
Epirubicin—Hypersensitivity—Vincristine—muscle cancer	1.01e-05	0.000258	CcSEcCtD
Epirubicin—Eosinophilia—Doxorubicin—muscle cancer	1e-05	0.000257	CcSEcCtD
Epirubicin—Sweating—Methotrexate—muscle cancer	9.99e-06	0.000256	CcSEcCtD
Epirubicin—Paraesthesia—Etoposide—muscle cancer	9.97e-06	0.000255	CcSEcCtD
Epirubicin—Haematuria—Methotrexate—muscle cancer	9.94e-06	0.000255	CcSEcCtD
Epirubicin—Pancreatitis—Doxorubicin—muscle cancer	9.93e-06	0.000254	CcSEcCtD
Epirubicin—Dyspnoea—Etoposide—muscle cancer	9.9e-06	0.000253	CcSEcCtD
Epirubicin—Somnolence—Etoposide—muscle cancer	9.87e-06	0.000253	CcSEcCtD
Epirubicin—Angina pectoris—Doxorubicin—muscle cancer	9.86e-06	0.000253	CcSEcCtD
Epirubicin—Hepatobiliary disease—Methotrexate—muscle cancer	9.86e-06	0.000252	CcSEcCtD
Epirubicin—Epistaxis—Methotrexate—muscle cancer	9.83e-06	0.000252	CcSEcCtD
Epirubicin—Asthenia—Vincristine—muscle cancer	9.83e-06	0.000252	CcSEcCtD
Epirubicin—Vomiting—Dactinomycin—muscle cancer	9.75e-06	0.00025	CcSEcCtD
Epirubicin—Bronchitis—Doxorubicin—muscle cancer	9.74e-06	0.000249	CcSEcCtD
Epirubicin—Agranulocytosis—Methotrexate—muscle cancer	9.73e-06	0.000249	CcSEcCtD
Epirubicin—PLA2G4A—Hemostasis—IGF2—muscle cancer	9.7e-06	0.00214	CbGpPWpGaD
Epirubicin—Rash—Dactinomycin—muscle cancer	9.67e-06	0.000248	CcSEcCtD
Epirubicin—Decreased appetite—Etoposide—muscle cancer	9.65e-06	0.000247	CcSEcCtD
Epirubicin—YWHAG—Cell Cycle, Mitotic—CDKN2A—muscle cancer	9.62e-06	0.00212	CbGpPWpGaD
Epirubicin—Pancytopenia—Doxorubicin—muscle cancer	9.61e-06	0.000246	CcSEcCtD
Epirubicin—Gastrointestinal disorder—Etoposide—muscle cancer	9.58e-06	0.000245	CcSEcCtD
Epirubicin—Fatigue—Etoposide—muscle cancer	9.57e-06	0.000245	CcSEcCtD
Epirubicin—Constipation—Etoposide—muscle cancer	9.49e-06	0.000243	CcSEcCtD
Epirubicin—Pain—Etoposide—muscle cancer	9.49e-06	0.000243	CcSEcCtD
Epirubicin—Dysuria—Doxorubicin—muscle cancer	9.47e-06	0.000242	CcSEcCtD
Epirubicin—Neutropenia—Doxorubicin—muscle cancer	9.47e-06	0.000242	CcSEcCtD
Epirubicin—Upper respiratory tract infection—Doxorubicin—muscle cancer	9.41e-06	0.000241	CcSEcCtD
Epirubicin—Haemoglobin—Methotrexate—muscle cancer	9.41e-06	0.000241	CcSEcCtD
Epirubicin—Diarrhoea—Vincristine—muscle cancer	9.38e-06	0.00024	CcSEcCtD
Epirubicin—Hepatitis—Methotrexate—muscle cancer	9.36e-06	0.00024	CcSEcCtD
Epirubicin—Haemorrhage—Methotrexate—muscle cancer	9.36e-06	0.00024	CcSEcCtD
Epirubicin—Pollakiuria—Doxorubicin—muscle cancer	9.35e-06	0.000239	CcSEcCtD
Epirubicin—ABCC1—Metabolism—FH—muscle cancer	9.33e-06	0.00206	CbGpPWpGaD
Epirubicin—Pharyngitis—Methotrexate—muscle cancer	9.29e-06	0.000238	CcSEcCtD
Epirubicin—Urinary tract disorder—Methotrexate—muscle cancer	9.24e-06	0.000237	CcSEcCtD
Epirubicin—Photosensitivity reaction—Doxorubicin—muscle cancer	9.24e-06	0.000237	CcSEcCtD
Epirubicin—Weight increased—Doxorubicin—muscle cancer	9.21e-06	0.000236	CcSEcCtD
Epirubicin—Urethral disorder—Methotrexate—muscle cancer	9.17e-06	0.000235	CcSEcCtD
Epirubicin—Weight decreased—Doxorubicin—muscle cancer	9.16e-06	0.000235	CcSEcCtD
Epirubicin—Feeling abnormal—Etoposide—muscle cancer	9.15e-06	0.000234	CcSEcCtD
Epirubicin—Hyperglycaemia—Doxorubicin—muscle cancer	9.13e-06	0.000234	CcSEcCtD
Epirubicin—Nausea—Dactinomycin—muscle cancer	9.11e-06	0.000233	CcSEcCtD
Epirubicin—Pneumonia—Doxorubicin—muscle cancer	9.08e-06	0.000232	CcSEcCtD
Epirubicin—Gastrointestinal pain—Etoposide—muscle cancer	9.08e-06	0.000232	CcSEcCtD
Epirubicin—Dizziness—Vincristine—muscle cancer	9.06e-06	0.000232	CcSEcCtD
Epirubicin—Drowsiness—Doxorubicin—muscle cancer	9.03e-06	0.000231	CcSEcCtD
Epirubicin—Infestation—Doxorubicin—muscle cancer	9.03e-06	0.000231	CcSEcCtD
Epirubicin—Infestation NOS—Doxorubicin—muscle cancer	9.03e-06	0.000231	CcSEcCtD
Epirubicin—Visual impairment—Methotrexate—muscle cancer	9.02e-06	0.000231	CcSEcCtD
Epirubicin—Stevens-Johnson syndrome—Doxorubicin—muscle cancer	8.95e-06	0.000229	CcSEcCtD
Epirubicin—Renal failure—Doxorubicin—muscle cancer	8.87e-06	0.000227	CcSEcCtD
Epirubicin—PLA2G4A—Integrated Pancreatic Cancer Pathway—VEGFA—muscle cancer	8.87e-06	0.00196	CbGpPWpGaD
Epirubicin—Erythema multiforme—Methotrexate—muscle cancer	8.85e-06	0.000227	CcSEcCtD
Epirubicin—Neuropathy peripheral—Doxorubicin—muscle cancer	8.85e-06	0.000227	CcSEcCtD
Epirubicin—Urticaria—Etoposide—muscle cancer	8.82e-06	0.000226	CcSEcCtD
Epirubicin—Stomatitis—Doxorubicin—muscle cancer	8.8e-06	0.000225	CcSEcCtD
Epirubicin—Jaundice—Doxorubicin—muscle cancer	8.8e-06	0.000225	CcSEcCtD
Epirubicin—Abdominal pain—Etoposide—muscle cancer	8.78e-06	0.000225	CcSEcCtD
Epirubicin—Body temperature increased—Etoposide—muscle cancer	8.78e-06	0.000225	CcSEcCtD
Epirubicin—Conjunctivitis—Doxorubicin—muscle cancer	8.77e-06	0.000225	CcSEcCtD
Epirubicin—Urinary tract infection—Doxorubicin—muscle cancer	8.77e-06	0.000225	CcSEcCtD
Epirubicin—Eye disorder—Methotrexate—muscle cancer	8.75e-06	0.000224	CcSEcCtD
Epirubicin—Tinnitus—Methotrexate—muscle cancer	8.73e-06	0.000223	CcSEcCtD
Epirubicin—Vomiting—Vincristine—muscle cancer	8.71e-06	0.000223	CcSEcCtD
Epirubicin—Cardiac disorder—Methotrexate—muscle cancer	8.69e-06	0.000222	CcSEcCtD
Epirubicin—Sweating—Doxorubicin—muscle cancer	8.65e-06	0.000222	CcSEcCtD
Epirubicin—Rash—Vincristine—muscle cancer	8.64e-06	0.000221	CcSEcCtD
Epirubicin—Dermatitis—Vincristine—muscle cancer	8.63e-06	0.000221	CcSEcCtD
Epirubicin—Haematuria—Doxorubicin—muscle cancer	8.61e-06	0.00022	CcSEcCtD
Epirubicin—YWHAG—Cell Cycle—CDKN2A—muscle cancer	8.61e-06	0.0019	CbGpPWpGaD
Epirubicin—Headache—Vincristine—muscle cancer	8.58e-06	0.00022	CcSEcCtD
Epirubicin—Hepatobiliary disease—Doxorubicin—muscle cancer	8.54e-06	0.000219	CcSEcCtD
Epirubicin—Epistaxis—Doxorubicin—muscle cancer	8.51e-06	0.000218	CcSEcCtD
Epirubicin—Angiopathy—Methotrexate—muscle cancer	8.49e-06	0.000217	CcSEcCtD
Epirubicin—Sinusitis—Doxorubicin—muscle cancer	8.47e-06	0.000217	CcSEcCtD
Epirubicin—Immune system disorder—Methotrexate—muscle cancer	8.45e-06	0.000216	CcSEcCtD
Epirubicin—Mediastinal disorder—Methotrexate—muscle cancer	8.43e-06	0.000216	CcSEcCtD
Epirubicin—Agranulocytosis—Doxorubicin—muscle cancer	8.42e-06	0.000216	CcSEcCtD
Epirubicin—Chills—Methotrexate—muscle cancer	8.4e-06	0.000215	CcSEcCtD
Epirubicin—YWHAG—Cell Cycle—MDM2—muscle cancer	8.35e-06	0.00184	CbGpPWpGaD
Epirubicin—Alopecia—Methotrexate—muscle cancer	8.27e-06	0.000212	CcSEcCtD
Epirubicin—Bradycardia—Doxorubicin—muscle cancer	8.25e-06	0.000211	CcSEcCtD
Epirubicin—Mental disorder—Methotrexate—muscle cancer	8.2e-06	0.00021	CcSEcCtD
Epirubicin—Hypersensitivity—Etoposide—muscle cancer	8.18e-06	0.000209	CcSEcCtD
Epirubicin—Malnutrition—Methotrexate—muscle cancer	8.15e-06	0.000209	CcSEcCtD
Epirubicin—Erythema—Methotrexate—muscle cancer	8.15e-06	0.000209	CcSEcCtD
Epirubicin—Haemoglobin—Doxorubicin—muscle cancer	8.14e-06	0.000209	CcSEcCtD
Epirubicin—Nausea—Vincristine—muscle cancer	8.14e-06	0.000208	CcSEcCtD
Epirubicin—Rhinitis—Doxorubicin—muscle cancer	8.12e-06	0.000208	CcSEcCtD
Epirubicin—Hepatitis—Doxorubicin—muscle cancer	8.1e-06	0.000207	CcSEcCtD
Epirubicin—Haemorrhage—Doxorubicin—muscle cancer	8.1e-06	0.000207	CcSEcCtD
Epirubicin—PLA2G4A—Signaling by GPCR—PTCH1—muscle cancer	8.07e-06	0.00178	CbGpPWpGaD
Epirubicin—Hypoaesthesia—Doxorubicin—muscle cancer	8.06e-06	0.000206	CcSEcCtD
Epirubicin—Pharyngitis—Doxorubicin—muscle cancer	8.04e-06	0.000206	CcSEcCtD
Epirubicin—Urinary tract disorder—Doxorubicin—muscle cancer	8e-06	0.000205	CcSEcCtD
Epirubicin—Oedema peripheral—Doxorubicin—muscle cancer	7.98e-06	0.000204	CcSEcCtD
Epirubicin—Dysgeusia—Methotrexate—muscle cancer	7.98e-06	0.000204	CcSEcCtD
Epirubicin—Asthenia—Etoposide—muscle cancer	7.96e-06	0.000204	CcSEcCtD
Epirubicin—Connective tissue disorder—Doxorubicin—muscle cancer	7.96e-06	0.000204	CcSEcCtD
Epirubicin—Urethral disorder—Doxorubicin—muscle cancer	7.94e-06	0.000203	CcSEcCtD
Epirubicin—PLA2G4A—Platelet activation, signaling and aggregation—VEGFA—muscle cancer	7.89e-06	0.00174	CbGpPWpGaD
Epirubicin—Back pain—Methotrexate—muscle cancer	7.88e-06	0.000202	CcSEcCtD
Epirubicin—Pruritus—Etoposide—muscle cancer	7.85e-06	0.000201	CcSEcCtD
Epirubicin—Visual impairment—Doxorubicin—muscle cancer	7.81e-06	0.0002	CcSEcCtD
Epirubicin—TOP2A—Integrated Pancreatic Cancer Pathway—TP53—muscle cancer	7.74e-06	0.00171	CbGpPWpGaD
Epirubicin—Vision blurred—Methotrexate—muscle cancer	7.68e-06	0.000197	CcSEcCtD
Epirubicin—Erythema multiforme—Doxorubicin—muscle cancer	7.66e-06	0.000196	CcSEcCtD
Epirubicin—Diarrhoea—Etoposide—muscle cancer	7.6e-06	0.000194	CcSEcCtD
Epirubicin—Eye disorder—Doxorubicin—muscle cancer	7.57e-06	0.000194	CcSEcCtD
Epirubicin—Ill-defined disorder—Methotrexate—muscle cancer	7.56e-06	0.000194	CcSEcCtD
Epirubicin—Tinnitus—Doxorubicin—muscle cancer	7.56e-06	0.000193	CcSEcCtD
Epirubicin—Anaemia—Methotrexate—muscle cancer	7.53e-06	0.000193	CcSEcCtD
Epirubicin—Cardiac disorder—Doxorubicin—muscle cancer	7.52e-06	0.000193	CcSEcCtD
Epirubicin—Flushing—Doxorubicin—muscle cancer	7.52e-06	0.000193	CcSEcCtD
Epirubicin—TOP2A—Circadian rythm related genes—TP53—muscle cancer	7.43e-06	0.00164	CbGpPWpGaD
Epirubicin—Angiopathy—Doxorubicin—muscle cancer	7.35e-06	0.000188	CcSEcCtD
Epirubicin—Malaise—Methotrexate—muscle cancer	7.35e-06	0.000188	CcSEcCtD
Epirubicin—Dizziness—Etoposide—muscle cancer	7.34e-06	0.000188	CcSEcCtD
Epirubicin—Immune system disorder—Doxorubicin—muscle cancer	7.32e-06	0.000187	CcSEcCtD
Epirubicin—Vertigo—Methotrexate—muscle cancer	7.32e-06	0.000187	CcSEcCtD
Epirubicin—Mediastinal disorder—Doxorubicin—muscle cancer	7.3e-06	0.000187	CcSEcCtD
Epirubicin—Leukopenia—Methotrexate—muscle cancer	7.29e-06	0.000187	CcSEcCtD
Epirubicin—Chills—Doxorubicin—muscle cancer	7.27e-06	0.000186	CcSEcCtD
Epirubicin—Arrhythmia—Doxorubicin—muscle cancer	7.24e-06	0.000185	CcSEcCtD
Epirubicin—Alopecia—Doxorubicin—muscle cancer	7.16e-06	0.000183	CcSEcCtD
Epirubicin—Cough—Methotrexate—muscle cancer	7.11e-06	0.000182	CcSEcCtD
Epirubicin—Mental disorder—Doxorubicin—muscle cancer	7.1e-06	0.000182	CcSEcCtD
Epirubicin—Convulsion—Methotrexate—muscle cancer	7.06e-06	0.000181	CcSEcCtD
Epirubicin—Vomiting—Etoposide—muscle cancer	7.06e-06	0.000181	CcSEcCtD
Epirubicin—Malnutrition—Doxorubicin—muscle cancer	7.05e-06	0.000181	CcSEcCtD
Epirubicin—Erythema—Doxorubicin—muscle cancer	7.05e-06	0.000181	CcSEcCtD
Epirubicin—Rash—Etoposide—muscle cancer	7e-06	0.000179	CcSEcCtD
Epirubicin—Dermatitis—Etoposide—muscle cancer	6.99e-06	0.000179	CcSEcCtD
Epirubicin—Headache—Etoposide—muscle cancer	6.95e-06	0.000178	CcSEcCtD
Epirubicin—Flatulence—Doxorubicin—muscle cancer	6.95e-06	0.000178	CcSEcCtD
Epirubicin—Chest pain—Methotrexate—muscle cancer	6.94e-06	0.000178	CcSEcCtD
Epirubicin—Arthralgia—Methotrexate—muscle cancer	6.94e-06	0.000178	CcSEcCtD
Epirubicin—Myalgia—Methotrexate—muscle cancer	6.94e-06	0.000178	CcSEcCtD
Epirubicin—Tension—Doxorubicin—muscle cancer	6.92e-06	0.000177	CcSEcCtD
Epirubicin—Dysgeusia—Doxorubicin—muscle cancer	6.91e-06	0.000177	CcSEcCtD
Epirubicin—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—muscle cancer	6.89e-06	0.000176	CcSEcCtD
Epirubicin—Discomfort—Methotrexate—muscle cancer	6.85e-06	0.000175	CcSEcCtD
Epirubicin—Nervousness—Doxorubicin—muscle cancer	6.85e-06	0.000175	CcSEcCtD
Epirubicin—Back pain—Doxorubicin—muscle cancer	6.82e-06	0.000175	CcSEcCtD
Epirubicin—PLA2G4A—Signaling by GPCR—CNR1—muscle cancer	6.81e-06	0.0015	CbGpPWpGaD
Epirubicin—Muscle spasms—Doxorubicin—muscle cancer	6.78e-06	0.000174	CcSEcCtD
Epirubicin—TOP2A—Cell Cycle, Mitotic—CDKN2A—muscle cancer	6.73e-06	0.00148	CbGpPWpGaD
Epirubicin—UGT2B7—Metabolism—MED12—muscle cancer	6.73e-06	0.00148	CbGpPWpGaD
Epirubicin—Confusional state—Methotrexate—muscle cancer	6.7e-06	0.000172	CcSEcCtD
Epirubicin—PLA2G4A—Integrated Pancreatic Cancer Pathway—TP53—muscle cancer	6.7e-06	0.00148	CbGpPWpGaD
Epirubicin—Anaphylactic shock—Methotrexate—muscle cancer	6.65e-06	0.00017	CcSEcCtD
Epirubicin—Vision blurred—Doxorubicin—muscle cancer	6.65e-06	0.00017	CcSEcCtD
Epirubicin—Infection—Methotrexate—muscle cancer	6.61e-06	0.000169	CcSEcCtD
Epirubicin—PLA2G4A—Metabolism—MED12—muscle cancer	6.6e-06	0.00145	CbGpPWpGaD
Epirubicin—Nausea—Etoposide—muscle cancer	6.59e-06	0.000169	CcSEcCtD
Epirubicin—Ill-defined disorder—Doxorubicin—muscle cancer	6.55e-06	0.000168	CcSEcCtD
Epirubicin—Nervous system disorder—Methotrexate—muscle cancer	6.52e-06	0.000167	CcSEcCtD
Epirubicin—Anaemia—Doxorubicin—muscle cancer	6.52e-06	0.000167	CcSEcCtD
Epirubicin—Thrombocytopenia—Methotrexate—muscle cancer	6.51e-06	0.000167	CcSEcCtD
Epirubicin—Agitation—Doxorubicin—muscle cancer	6.48e-06	0.000166	CcSEcCtD
Epirubicin—Skin disorder—Methotrexate—muscle cancer	6.46e-06	0.000165	CcSEcCtD
Epirubicin—Hyperhidrosis—Methotrexate—muscle cancer	6.43e-06	0.000165	CcSEcCtD
Epirubicin—Malaise—Doxorubicin—muscle cancer	6.36e-06	0.000163	CcSEcCtD
Epirubicin—Vertigo—Doxorubicin—muscle cancer	6.34e-06	0.000162	CcSEcCtD
Epirubicin—Anorexia—Methotrexate—muscle cancer	6.34e-06	0.000162	CcSEcCtD
Epirubicin—Syncope—Doxorubicin—muscle cancer	6.33e-06	0.000162	CcSEcCtD
Epirubicin—AURKA—Cell Cycle—TP53—muscle cancer	6.32e-06	0.00139	CbGpPWpGaD
Epirubicin—Leukopenia—Doxorubicin—muscle cancer	6.31e-06	0.000162	CcSEcCtD
Epirubicin—Palpitations—Doxorubicin—muscle cancer	6.23e-06	0.00016	CcSEcCtD
Epirubicin—Hypotension—Methotrexate—muscle cancer	6.21e-06	0.000159	CcSEcCtD
Epirubicin—Loss of consciousness—Doxorubicin—muscle cancer	6.2e-06	0.000159	CcSEcCtD
Epirubicin—DHCR7—Metabolism—PTGS2—muscle cancer	6.19e-06	0.00136	CbGpPWpGaD
Epirubicin—Cough—Doxorubicin—muscle cancer	6.16e-06	0.000158	CcSEcCtD
Epirubicin—UGT2B7—Metabolism—ENO2—muscle cancer	6.13e-06	0.00135	CbGpPWpGaD
Epirubicin—Convulsion—Doxorubicin—muscle cancer	6.11e-06	0.000156	CcSEcCtD
Epirubicin—Hypertension—Doxorubicin—muscle cancer	6.09e-06	0.000156	CcSEcCtD
Epirubicin—Musculoskeletal discomfort—Methotrexate—muscle cancer	6.06e-06	0.000155	CcSEcCtD
Epirubicin—TOP2A—Cell Cycle—CDKN2A—muscle cancer	6.02e-06	0.00133	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism—ENO2—muscle cancer	6.01e-06	0.00133	CbGpPWpGaD
Epirubicin—Insomnia—Methotrexate—muscle cancer	6.01e-06	0.000154	CcSEcCtD
Epirubicin—Chest pain—Doxorubicin—muscle cancer	6.01e-06	0.000154	CcSEcCtD
Epirubicin—Myalgia—Doxorubicin—muscle cancer	6.01e-06	0.000154	CcSEcCtD
Epirubicin—Arthralgia—Doxorubicin—muscle cancer	6.01e-06	0.000154	CcSEcCtD
Epirubicin—Anxiety—Doxorubicin—muscle cancer	5.99e-06	0.000153	CcSEcCtD
Epirubicin—Paraesthesia—Methotrexate—muscle cancer	5.97e-06	0.000153	CcSEcCtD
Epirubicin—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—muscle cancer	5.96e-06	0.000153	CcSEcCtD
Epirubicin—Discomfort—Doxorubicin—muscle cancer	5.93e-06	0.000152	CcSEcCtD
Epirubicin—Dyspnoea—Methotrexate—muscle cancer	5.93e-06	0.000152	CcSEcCtD
Epirubicin—Somnolence—Methotrexate—muscle cancer	5.91e-06	0.000151	CcSEcCtD
Epirubicin—Dry mouth—Doxorubicin—muscle cancer	5.87e-06	0.00015	CcSEcCtD
Epirubicin—Dyspepsia—Methotrexate—muscle cancer	5.85e-06	0.00015	CcSEcCtD
Epirubicin—TOP2A—Cell Cycle—MDM2—muscle cancer	5.84e-06	0.00129	CbGpPWpGaD
Epirubicin—Confusional state—Doxorubicin—muscle cancer	5.81e-06	0.000149	CcSEcCtD
Epirubicin—Decreased appetite—Methotrexate—muscle cancer	5.78e-06	0.000148	CcSEcCtD
Epirubicin—Oedema—Doxorubicin—muscle cancer	5.76e-06	0.000147	CcSEcCtD
Epirubicin—Anaphylactic shock—Doxorubicin—muscle cancer	5.76e-06	0.000147	CcSEcCtD
Epirubicin—Gastrointestinal disorder—Methotrexate—muscle cancer	5.74e-06	0.000147	CcSEcCtD
Epirubicin—ABCC1—Disease—ENO2—muscle cancer	5.74e-06	0.00126	CbGpPWpGaD
Epirubicin—Fatigue—Methotrexate—muscle cancer	5.73e-06	0.000147	CcSEcCtD
Epirubicin—Infection—Doxorubicin—muscle cancer	5.72e-06	0.000146	CcSEcCtD
Epirubicin—Pain—Methotrexate—muscle cancer	5.69e-06	0.000146	CcSEcCtD
Epirubicin—Shock—Doxorubicin—muscle cancer	5.66e-06	0.000145	CcSEcCtD
Epirubicin—Nervous system disorder—Doxorubicin—muscle cancer	5.65e-06	0.000145	CcSEcCtD
Epirubicin—Thrombocytopenia—Doxorubicin—muscle cancer	5.64e-06	0.000144	CcSEcCtD
Epirubicin—Tachycardia—Doxorubicin—muscle cancer	5.62e-06	0.000144	CcSEcCtD
Epirubicin—Skin disorder—Doxorubicin—muscle cancer	5.59e-06	0.000143	CcSEcCtD
Epirubicin—Hyperhidrosis—Doxorubicin—muscle cancer	5.57e-06	0.000143	CcSEcCtD
Epirubicin—Anorexia—Doxorubicin—muscle cancer	5.49e-06	0.000141	CcSEcCtD
Epirubicin—Feeling abnormal—Methotrexate—muscle cancer	5.48e-06	0.00014	CcSEcCtD
Epirubicin—Gastrointestinal pain—Methotrexate—muscle cancer	5.44e-06	0.000139	CcSEcCtD
Epirubicin—Hypotension—Doxorubicin—muscle cancer	5.38e-06	0.000138	CcSEcCtD
Epirubicin—Urticaria—Methotrexate—muscle cancer	5.28e-06	0.000135	CcSEcCtD
Epirubicin—ABCC1—Metabolism—MED12—muscle cancer	5.27e-06	0.00116	CbGpPWpGaD
Epirubicin—Abdominal pain—Methotrexate—muscle cancer	5.26e-06	0.000135	CcSEcCtD
Epirubicin—Body temperature increased—Methotrexate—muscle cancer	5.26e-06	0.000135	CcSEcCtD
Epirubicin—Musculoskeletal discomfort—Doxorubicin—muscle cancer	5.25e-06	0.000134	CcSEcCtD
Epirubicin—ABCC1—Disease—HMGA1—muscle cancer	5.21e-06	0.00115	CbGpPWpGaD
Epirubicin—Insomnia—Doxorubicin—muscle cancer	5.21e-06	0.000133	CcSEcCtD
Epirubicin—Paraesthesia—Doxorubicin—muscle cancer	5.17e-06	0.000132	CcSEcCtD
Epirubicin—Dyspnoea—Doxorubicin—muscle cancer	5.13e-06	0.000131	CcSEcCtD
Epirubicin—Somnolence—Doxorubicin—muscle cancer	5.12e-06	0.000131	CcSEcCtD
Epirubicin—Dyspepsia—Doxorubicin—muscle cancer	5.07e-06	0.00013	CcSEcCtD
Epirubicin—Decreased appetite—Doxorubicin—muscle cancer	5e-06	0.000128	CcSEcCtD
Epirubicin—Gastrointestinal disorder—Doxorubicin—muscle cancer	4.97e-06	0.000127	CcSEcCtD
Epirubicin—Fatigue—Doxorubicin—muscle cancer	4.96e-06	0.000127	CcSEcCtD
Epirubicin—Constipation—Doxorubicin—muscle cancer	4.92e-06	0.000126	CcSEcCtD
Epirubicin—Pain—Doxorubicin—muscle cancer	4.92e-06	0.000126	CcSEcCtD
Epirubicin—Hypersensitivity—Methotrexate—muscle cancer	4.9e-06	0.000125	CcSEcCtD
Epirubicin—ABCC1—Metabolism—ENO2—muscle cancer	4.81e-06	0.00106	CbGpPWpGaD
Epirubicin—YWHAG—Cell Cycle—TP53—muscle cancer	4.79e-06	0.00106	CbGpPWpGaD
Epirubicin—Asthenia—Methotrexate—muscle cancer	4.77e-06	0.000122	CcSEcCtD
Epirubicin—PLA2G4A—Signaling Pathways—PTCH1—muscle cancer	4.77e-06	0.00105	CbGpPWpGaD
Epirubicin—Feeling abnormal—Doxorubicin—muscle cancer	4.74e-06	0.000121	CcSEcCtD
Epirubicin—Gastrointestinal pain—Doxorubicin—muscle cancer	4.71e-06	0.000121	CcSEcCtD
Epirubicin—Pruritus—Methotrexate—muscle cancer	4.7e-06	0.00012	CcSEcCtD
Epirubicin—PLA2G4A—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	4.7e-06	0.00104	CbGpPWpGaD
Epirubicin—ABCC1—Disease—FOXO4—muscle cancer	4.68e-06	0.00103	CbGpPWpGaD
Epirubicin—Urticaria—Doxorubicin—muscle cancer	4.57e-06	0.000117	CcSEcCtD
Epirubicin—Abdominal pain—Doxorubicin—muscle cancer	4.55e-06	0.000117	CcSEcCtD
Epirubicin—Body temperature increased—Doxorubicin—muscle cancer	4.55e-06	0.000117	CcSEcCtD
Epirubicin—Diarrhoea—Methotrexate—muscle cancer	4.55e-06	0.000116	CcSEcCtD
Epirubicin—Dizziness—Methotrexate—muscle cancer	4.4e-06	0.000113	CcSEcCtD
Epirubicin—Hypersensitivity—Doxorubicin—muscle cancer	4.24e-06	0.000109	CcSEcCtD
Epirubicin—Vomiting—Methotrexate—muscle cancer	4.23e-06	0.000108	CcSEcCtD
Epirubicin—Rash—Methotrexate—muscle cancer	4.19e-06	0.000107	CcSEcCtD
Epirubicin—Dermatitis—Methotrexate—muscle cancer	4.19e-06	0.000107	CcSEcCtD
Epirubicin—Headache—Methotrexate—muscle cancer	4.17e-06	0.000107	CcSEcCtD
Epirubicin—Asthenia—Doxorubicin—muscle cancer	4.13e-06	0.000106	CcSEcCtD
Epirubicin—PLA2G4A—Signaling Pathways—FOXO4—muscle cancer	4.1e-06	0.000904	CbGpPWpGaD
Epirubicin—Pruritus—Doxorubicin—muscle cancer	4.07e-06	0.000104	CcSEcCtD
Epirubicin—PLA2G4A—Hemostasis—VEGFA—muscle cancer	4.07e-06	0.000897	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—CNR1—muscle cancer	4.02e-06	0.000887	CbGpPWpGaD
Epirubicin—Nausea—Methotrexate—muscle cancer	3.95e-06	0.000101	CcSEcCtD
Epirubicin—Diarrhoea—Doxorubicin—muscle cancer	3.94e-06	0.000101	CcSEcCtD
Epirubicin—Dizziness—Doxorubicin—muscle cancer	3.81e-06	9.75e-05	CcSEcCtD
Epirubicin—ABCC1—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	3.76e-06	0.000828	CbGpPWpGaD
Epirubicin—Vomiting—Doxorubicin—muscle cancer	3.66e-06	9.37e-05	CcSEcCtD
Epirubicin—Rash—Doxorubicin—muscle cancer	3.63e-06	9.29e-05	CcSEcCtD
Epirubicin—Dermatitis—Doxorubicin—muscle cancer	3.63e-06	9.29e-05	CcSEcCtD
Epirubicin—Headache—Doxorubicin—muscle cancer	3.61e-06	9.23e-05	CcSEcCtD
Epirubicin—ABCC1—Disease—FOXO1—muscle cancer	3.45e-06	0.000761	CbGpPWpGaD
Epirubicin—Nausea—Doxorubicin—muscle cancer	3.42e-06	8.76e-05	CcSEcCtD
Epirubicin—TOP2A—Cell Cycle—TP53—muscle cancer	3.35e-06	0.000738	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—IGF2—muscle cancer	3.29e-06	0.000725	CbGpPWpGaD
Epirubicin—PLA2G4A—Hemostasis—TP53—muscle cancer	3.07e-06	0.000678	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—FOXO1—muscle cancer	3.03e-06	0.000667	CbGpPWpGaD
Epirubicin—ABCC1—Disease—KIT—muscle cancer	2.63e-06	0.00058	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—KIT—muscle cancer	2.31e-06	0.000508	CbGpPWpGaD
Epirubicin—UGT2B7—Metabolism—PTGS2—muscle cancer	2.14e-06	0.000471	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism—PTGS2—muscle cancer	2.09e-06	0.000462	CbGpPWpGaD
Epirubicin—ABCC1—Disease—MDM2—muscle cancer	2.07e-06	0.000457	CbGpPWpGaD
Epirubicin—ABCC1—Disease—PTGS2—muscle cancer	2e-06	0.00044	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—MDM2—muscle cancer	1.82e-06	0.0004	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—PTGS2—muscle cancer	1.67e-06	0.000369	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—VEGFA—muscle cancer	1.38e-06	0.000304	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—TP53—muscle cancer	1.04e-06	0.00023	CbGpPWpGaD
